Market revenue in 2023 | USD 717.1 million |
Market revenue in 2030 | USD 1,666.3 million |
Growth rate | 12.8% (CAGR from 2023 to 2030) |
Largest segment | Blood sample |
Fastest growing segment | Blood Sample |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Blood Sample |
Key market players worldwide | ANGLE PLC, Guardant Health Inc, Myriad Genetics Inc, Biocept Inc, Lucence Health, Roche, Qiagen NV, Illumina Inc, Thermo Fisher Scientific Inc, Epigenomics AG, Oncimmune, Freenome |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liquid biopsy market will help companies and investors design strategic landscapes.
Blood sample was the largest segment with a revenue share of 73.2% in 2023. Horizon Databook has segmented the UK liquid biopsy market based on blood sample covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of sophisticated healthcare infrastructure, collaborations between key market players, and launch of novel products are anticipated to contribute to market growth in the UK. Government support & initiatives are expected to further propel the country’s cancer diagnostics market in the coming years.
The deal follows a USD 25 million minority equity investment by the company in Inivata the previous year, wherein NeoGenomics granted the option to buy Inivata for USD 390 million if exercised before the end of 2021.
Moreover, an increasing focus on R&D of novel diagnostics is further anticipated to drive market growth. For instance, in March 2023, Nonacus Limited, in collaboration with researchers at the University of Birmingham, announced the launch of a urine-based bladder cancer assay, Galeas Bladder.
Horizon Databook provides a detailed overview of country-level data and insights on the UK liquid biopsy market , including forecasts for subscribers. This country databook contains high-level insights into UK liquid biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account